Line 31: |
Line 31: |
| :*Canine cognitive dysfunction. <ref>Selegiline hydrochloride [https://www.zoetisus.com/_locale-assets/mcm-portal-assets/products/pdf/anipryl_pi.pdf data sheet]</ref> | | :*Canine cognitive dysfunction. <ref>Selegiline hydrochloride [https://www.zoetisus.com/_locale-assets/mcm-portal-assets/products/pdf/anipryl_pi.pdf data sheet]</ref> |
| *Unlicensed | | *Unlicensed |
− | :*Other fear related problems (including aggression) <font color="red">- have also read that can cause an increase in aggression? - does this depend on the cause of aggression as to whether appropriate?</font> | + | :*Other fear related problems (including fear-related aggression) |
| :*Spraying (fear related in cats) | | :*Spraying (fear related in cats) |
| :*Hyperactivity | | :*Hyperactivity |
Line 39: |
Line 39: |
| | | |
| ==Adverse Effects== | | ==Adverse Effects== |
| + | Adverse effects include: |
| *Agitation | | *Agitation |
| *GI signs (nausea, diarrhoea, usually transient) | | *GI signs (nausea, diarrhoea, usually transient) |
Line 48: |
Line 49: |
| *Itching | | *Itching |
| *Shaking | | *Shaking |
− | *Increased competitiveness and shifts in status relationships: both with people and [more probably] other dogs in the household. Especially important where status related problems already exist. | + | *Increased owner directed aggression and inter-dog competitive aggression (in cases where these problems already exist). |
| | | |
| '''Caution should be taken in if the animal suffers from any of the following pre-existing medical conditions:''' | | '''Caution should be taken in if the animal suffers from any of the following pre-existing medical conditions:''' |
| *Hyperadrenocorticism (not of pituitary origin) | | *Hyperadrenocorticism (not of pituitary origin) |
| + | *Owner-directed aggression |
| | | |
| '''Care should be taken if used in conjunction with any of the following drugs, which may interact and cause adverse effects:''' | | '''Care should be taken if used in conjunction with any of the following drugs, which may interact and cause adverse effects:''' |
Line 67: |
Line 69: |
| ==References== | | ==References== |
| <references/> | | <references/> |
− | {{unfinished}} | + | |
− | [[Category:To Do - Behaviour GGP]]
| + | <br><br> |
| + | {{Jon Bowen reviewed |
| + | |date=September 9, 2014 |
| + | }} |
| + | |
| + | {{Ceva}} |
| + | {{OpenPages}} |
| + | |
| [[Category:Pharmacological Approach to Problem Behaviour]] | | [[Category:Pharmacological Approach to Problem Behaviour]] |
− | [[Category:JBowen prereview]]
| |